Positive long term data has been reported from the phase 1 clinical trials of the CTX stem cell therapy for stroke patients who are left disabled, as per the ReNeuron Group PLC.
The company plans to present its data at the 2015 European Stroke Organisation Conference which will be held at Glasgow on Sunday.
11 patients taken in for the study were followed up for a long term after the treatment, and there were no immunological adverse events or cell related problems noted in any of the patients.
The only adverse events that turned up were those related to implantation procedures, or in patients who had an underlying medical condition.
Within just three months of treatment, improvements were seen in the neurological status and limb function of the patients, which seemed consistent all throughout the long term follow up.
“The data confirm the good safety profile of our CTX stem cell treatment in this setting and it is particularly gratifying to see that the functional improvements previously observed in the patients against baseline measurements have been maintained in long term follow up. We look forward to reporting data from our ongoing Phase II study with CTX in disabled stroke patients in due course,” the researchers said.